{
    "clinical_study": {
        "@rank": "146426", 
        "acronym": "ANGIOSWITCH", 
        "arm_group": {
            "arm_group_label": "Chemotherapy treatment", 
            "arm_group_type": "Experimental", 
            "description": "Chemotherapy treatment with Xelox or Xeliri and bevacizumab"
        }, 
        "brief_summary": {
            "textblock": "A group of colorectal cancer (CRC) patients treated with chemotherapy and Bevacizumab (Bev)\n      maintain the same sensitivity after progression to maintenance treatment because they remain\n      dependent on VEGF angiogenic mediator, while other patients in whom there is an angiogenic\n      switch (AS) become dependent on other angiogenic cytokines and become resistant to Bev\n      chemotherapy combinations ."
        }, 
        "brief_title": "Angiogenic Switch in Patients With Colorectal Cancer", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of stage IV colorectal adenocarcinoma.\n\n          -  Age \u2265 18 years .\n\n          -  Measurable disease by RECIST criteria.\n\n          -  Life expectancy \u2265 6 months.\n\n          -  Candidate to receive treatment with first-line chemotherapy.\n\n          -  Availability of tumor tissue.\n\n        Exclusion Criteria:\n\n          -  Patients who have received prior treatment with first-line chemotherapy for\n             metastatic disease.\n\n          -  Patients in whom there is contraindication to the administration of either drug used\n             in the study: capecitabine, irinotecan, oxaliplatin or Bev.\n\n          -  Patients receiving anticoagulant oral treatment.\n\n          -  Patient with diagnosis of other malignancies within 5 years prior to diagnosis except\n             basal cell carcinoma or cervical carcinoma \u00b7 in situ. \u00b7 The inclusion of patients\n             with malignant disease diagnosed more than 5 years ago without recurrence in the\n             previous 3 years will be analyzed individually\n\n          -  Patients with bone disease as the only manifestation of the disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 17, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02075086", 
            "org_study_id": "ANGIOSWITCH2011"
        }, 
        "intervention": {
            "arm_group_label": "Chemotherapy treatment", 
            "description": "Xelox or Xeliri Bevacizumab treatment", 
            "intervention_name": "Chemotherapy treatment", 
            "intervention_type": "Drug", 
            "other_name": [
                "Cytokines measure", 
                "Angiogenic study"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "angiogenic switch", 
            "plasma cytokines", 
            "Colon cancer"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "contact": {
                "email": "sofiaperea@hospitaldemadrid.com", 
                "last_name": "Sofia Perea, MD,PhD", 
                "phone": "+34 917567850"
            }, 
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28050"
                }, 
                "name": "Centro Integral oncol\u00f3gico Clara Campal"
            }, 
            "investigator": {
                "last_name": "Antonio Cubillo, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Angiogenic Switch as Predictor of Response to Chemotherapy in Patients With Metastatic Colorectal Cancer", 
        "overall_contact": {
            "email": "sofiaperea@hospitaldemadrid.com", 
            "last_name": "Sofia Perea, MD,PhD", 
            "phone": "+34 91 7567850"
        }, 
        "overall_official": {
            "affiliation": "Grupo Hospital de Madrid", 
            "last_name": "Antonio Cubillo, MD PhaD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Days from cycle one day one to progression", 
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02075086"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Grupo Hospital de Madrid", 
            "investigator_full_name": "Sofia Perea, Director Clinical Trials Unit.", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Feasibility of doing a clinical prospective trial with a measure od plasma citoquines.", 
            "measure": "Feasibility", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Grupo Hospital de Madrid", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Grupo Hospital de Madrid", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}